Log in

Fate Therapeutics Stock Price, News & Analysis (NASDAQ:FATE)

$14.25
+0.25 (+1.79 %)
(As of 10/14/2019 06:43 AM ET)
Today's Range
$13.82
Now: $14.25
$14.74
50-Day Range
$14.06
MA: $16.62
$18.79
52-Week Range
$11.00
Now: $14.25
$22.82
Volume954,478 shs
Average Volume832,524 shs
Market Capitalization$931.81 million
P/E RatioN/A
Dividend YieldN/A
Beta1.79
Fate Therapeutics, Inc operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FATE
CUSIPN/A
Phone858-875-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.74 million
Book Value$2.48 per share

Profitability

Net Income$-66,600,000.00
Net Margins-934.70%

Miscellaneous

Employees104
Market Cap$931.81 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive FATE News and Ratings via Email

Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.


Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics Inc (NASDAQ:FATE) released its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.04. The biopharmaceutical company earned $2.80 million during the quarter, compared to analysts' expectations of $1.09 million. Fate Therapeutics had a negative net margin of 934.70% and a negative return on equity of 50.05%. The firm's quarterly revenue was up 180.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.37) EPS. View Fate Therapeutics' Earnings History.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Fate Therapeutics.

What price target have analysts set for FATE?

16 brokers have issued twelve-month price objectives for Fate Therapeutics' shares. Their forecasts range from $17.00 to $32.00. On average, they expect Fate Therapeutics' stock price to reach $25.00 in the next year. This suggests a possible upside of 75.4% from the stock's current price. View Analyst Price Targets for Fate Therapeutics.

What is the consensus analysts' recommendation for Fate Therapeutics?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 hold rating and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.

Has Fate Therapeutics been receiving favorable news coverage?

Press coverage about FATE stock has been trending negative recently, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Fate Therapeutics earned a daily sentiment score of -2.6 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Fate Therapeutics.

Who are some of Fate Therapeutics' key competitors?

What other stocks do shareholders of Fate Therapeutics own?

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the folowing people:
  • J. Scott Wolchko, President, Chief Executive Officer & Director
  • Daniel D. Shoemaker, Chief Scientific Officer
  • Yu Waye Chu, Vice President-Clinical Development
  • Jim Beitel, Senior Vice President-Corporate Development
  • Bahram Valamehr, Chief Development Officer

How do I buy shares of Fate Therapeutics?

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $14.25.

How big of a company is Fate Therapeutics?

Fate Therapeutics has a market capitalization of $931.81 million and generates $4.74 million in revenue each year. The biopharmaceutical company earns $-66,600,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.View Additional Information About Fate Therapeutics.

What is Fate Therapeutics' official website?

The official website for Fate Therapeutics is http://www.fatetherapeutics.com/.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]


MarketBeat Community Rating for Fate Therapeutics (NASDAQ FATE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  349 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  568
MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe FATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Featured Article: Insider Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel